Pervasis Therapeutics, Inc.

Pervasis Therapeutics Granted Orphan Drug Designation for Vascugel®

Pervasis Therapeutics Granted Orphan Drug Designation for Vascugel®

May 5, 2009

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pervasis Therapeutics, Inc., a biotechnology company pioneering biologically active cellular therapies to treat vascular and other serious diseases, today announced that it has received Orphan Drug Designation for Vascugel®, a novel allogeneic cell therapy product that may restore natural repair and regeneration pathways in the vasculature, from the U.S. Food and Drug Administration (FDA).

Resolvyx Pharmaceuticals, Inc.

Resolvyx Presents Data Demonstrating Potential for Resolvin Therapeutics to Treat Corneal and Retinal Eye Diseases at ARVO 2009 Meeting

Resolvyx Presents Data Demonstrating Potential for Resolvin Therapeutics to Treat Corneal and Retinal Eye Diseases at ARVO 2009 Meeting

May 7, 2009

RX-10045 Promotes Corneal Epithelial Repair in Model System

Topical Administration of Resolvin Effective in Model of Wet AMD

Helicos BioSciences Corporation

Helicos Demonstrates The Utility of Its Single Molecule Sequencing Platform at Cold Spring Harbor Genome Conference

Helicos Demonstrates The Utility of Its Single Molecule Sequencing Platform at Cold Spring Harbor Genome Conference

May 8, 2009

The Helicos System Produces Better Scientific Results with Less Sequencing Required

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Granted Patents on Deuterium-Modified Compounds

Concert Pharmaceuticals Granted Patents on Deuterium-Modified Compounds

May 11, 2009

LEXINGTON, Mass -- Concert Pharmaceuticals, Inc. announced today that its first patents have been granted by the U.S. Patent and Trademark Office. These patents relate to specific compounds derived from Concert’s deuterium chemistry platform. U.S. Patents 7,514,068 and 7,528,131 specifically claim deuterium analogs of rimonabant and mosapride, respectively. In addition to these patents, Concert has over 100 pending U.S. patent applications and corresponding applications worldwide.

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals’ Scientific Advisory Board Members Recognized for Contributions to Cancer Research and Medicine

AVEO Pharmaceuticals’ Scientific Advisory Board Members Recognized for Contributions to Cancer Research and Medicine

May 13, 2009

SAB Members Elected to NAS and IOM; Honored with Awards from AACR and NFCR

Helicos BioSciences Corporation

Helicos BioSciences Reports Q1 2009 Financial Results

Helicos BioSciences Reports Q1 2009 Financial Results

May 14, 2009

Achieves First Instrument Revenue and Significant Milestones

CAMBRIDGE, Mass., May 14, 2009 -- Helicos BioSciences Corporation (NASDAQ: HLCS) announced today its financial results for the quarter ended March 31, 2009.

LS9

LS9 and Procter & Gamble Launch Sustainable Chemicals Partnership

LS9 and Procter & Gamble Launch Sustainable Chemicals Partnership

May 19, 2009

Confirms P&G’s Commitment to Sustainable Innovation

Accelerates LS9’s Entry into the Consumer Product Chemicals Market

Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals Appoints David Schenkein, M.D. as CEO and Duncan Higgons as COO

Agios Pharmaceuticals Appoints David Schenkein, M.D. as CEO and Duncan Higgons as COO

May 27, 2009

Industry Leaders Bring Deep Oncology and Company Building Experience

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals and GlaxoSmithKline Form Alliance to Develop Novel Deuterium Modified Drugs

Concert Pharmaceuticals and GlaxoSmithKline Form Alliance to Develop Novel Deuterium Modified Drugs

June 2, 2009

LEXINGTON, Mass. & LONDON -- Concert Pharmaceuticals and GlaxoSmithKline (NYSE: GSK) announced today that they will collaborate to develop and commercialize deuterium-containing medicines. The deal includes three of Concert’s research and development programs; namely, CTP-518, a protease inhibitor for the treatment of HIV expected to enter Phase I clinical trials in the second half of 2009, a preclinical compound for chronic renal disease, and a third research product in Concert’s pipeline.

TARIS Biomedical, Inc.

TARIS Biomedical Launches with $15 Million in Funding to Develop Innovative Drug-Device Therapies

TARIS Biomedical Launches with $15 Million in Funding to Develop Innovative Drug-Device Therapies

June 24, 2009

LEXINGTON, Mass. - (Business Wire) TARIS Biomedical, a specialty pharmaceutical company pioneering the field of drug-device convergence for targeted therapies, launched today and announced it has secured $15 million in Series A financing. Leading venture capital firms Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners co-led the investment in TARIS, which was founded by internationally renowned scientists from the Massachusetts Institute of Technology (MIT), Michael Cima, Ph.D.